Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces the potential...
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024Commercial and manufacturing infrastructure...
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approvalPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchiseUpdate on afami-cel launch plans to be provided at the April 18th...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed with...
Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ:...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford,...